Cardiovascular Systems, Inc. today announced that the results from its REACH PVI study were presented at the New Cardiovascular Horizons (NCVH) Conference.
This study prospectively evaluated acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease (PAD) in lower extremity lesions.
CSI’s low profile 5Fr, Extended Length Diamondback 360® and Stealth 360® Peripheral Orbital Atherectomy Systems (OAS) are the only atherectomy systems that allow radial access for the treatment of peripheral lesions.
The results of the REACH PVI study demonstrated that the use of orbital atherectomy in radial peripheral vascular interventions has a high rate of procedural and treatment success and is effective in reducing residual stenosis across all lesions. Ninety-eight percent of patients achieved procedural and treatment success. There were no reports of serious transradial access related events. Additionally, the study demonstrated short recovery time and length of stay, key factors in patient satisfaction.
National Primary Investigator for REACH PVI, Dr. Ankur Lodha, MD, Interventional Cardiologist, Cardiovascular Institute of the South, Lafayette, La., said, “It’s a fascinating time for peripheral interventions because the entire case can be done solely with radial artery access. Radial access can lead to better patient satisfaction and comfort, improved patient safety and is also beneficial to healthcare economics. CSI is leading the way with their peripheral orbital atherectomy device as it’s the only atherectomy system available that is designed to treat through the radial artery.”
Scott Ward, CSI Chairman, President, and Chief Executive Officer, said, “The positive data from REACH PVI confirms our belief that our low-profile OAS is uniquely positioned to safely treat patients suffering from PAD. Using an alternative access site, like radial, can provide shorter recovery time for patients, and reduced length of stay compared to femoral access. Our investment in this technology, and studies like REACH PVI, demonstrate our ongoing commitment to advancing medical evidence to support physicians and the patients they serve.”